PART I Item 1. B usiness. Overview We are a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. We pursue promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, we are advancing our mission to deliver new standards ...
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001193125-26-099362 | EDGAR | 95K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028346 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031143 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006839 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004002 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001564590-21-016312 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268066 | EDGAR | 20K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104551 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066384 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122795 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093320 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060535 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-060679 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040964 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021253 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024683 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016258 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009937 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-10 | 0001193125-26-099355 | EDGAR | 2K words |
| 2026-01-08 | 0001193125-26-006998 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310764 | EDGAR | — |
| 2025-11-21 | 0001193125-25-291448 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268041 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261799 | EDGAR | — |
| 2025-09-04 | 0000950170-25-112949 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104547 | EDGAR | — |
| 2025-06-12 | 0000950170-25-085425 | EDGAR | — |
| 2025-06-04 | 0000950170-25-081601 | EDGAR | — |
90 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001789972 |
| Ticker | CGEM |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.cullinantherapeutics.com |
| Listed | 2021-01-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report